EVENTIDE ASSET MANAGEMENT, LLC
Q3 2020 13F-HR Holdings
Net value change ($000)
+508,320
(11.0%)
New positions
25
Sold out positions
16
Turnover %
12.3%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2020
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| W | 54,444 | 48.1% |
| ANNX | 52,395 | NEW |
| ECL | 45,963 | NEW |
| GTM | 44,882 | NEW |
| CTAS | 44,266 | NEW |
| FVRR | 42,436 | 144.3% |
| SPT | 37,730 | NEW |
| CRWD | 37,597 | 38.0% |
| Freeline Therapeutics Holdings plc | 35,620 | NEW |
| TTD | 34,454 | 28.3% |
Top Reduces (Value $000, Stocks/ETFs)
| Aimmune Therapeutics, Inc. | -53,357 | -100.0% |
| SPLUNK INC | -41,410 | -54.8% |
| MOMENTA PHARMACEUTICALS INC | -40,323 | -100.0% |
| SMARTSHEET INC | -35,077 | -61.9% |
| LII | -33,514 | -56.4% |
| ZOGENIX, INC. | -32,717 | -100.0% |
| Karuna Therapeutics, Inc. | -30,763 | -30.6% |
| SRPT | -28,887 | -18.1% |
| Satsuma Pharmaceuticals, Inc. | -28,282 | -100.0% |
| PLRX | -26,719 | -30.2% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
112,500
(2.2% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|